Blog
RSS FeedPosted by Michael Wonder on 16 Aug 2018
How disruptive innovation by business and technology firms could improve population health
16 August 2018 - In 1990 the Centers for Disease Control and the US Preventive Services Task Force launched Healthy ...
Posted by Michael Wonder on 19 Jul 2018
Drug makers game the patent system and reap billions, FDA says
19 July 2018 - Gottlieb issues plan to boost biosimilar market, lower prices. ...
Posted by Michael Wonder on 17 Jul 2018
AbbVie announces Humira (adalimumab) patent license with Mylan
17 July 2018 - AbbVie announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product. ...
Posted by Michael Wonder on 13 Jul 2018
Health Canada ordered to release confidential drug company data on HPV vaccines
13 July 2018 - Federal government insisted drug companies' clinical trial data is 'confidential business information'. ...
Posted by Michael Wonder on 28 Jun 2018
Update on biosimilars
27 June 2018 - In the first half of 2018, Health Canada approved three biosimilars based on three different reference ...
Posted by Michael Wonder on 28 Jun 2018
The problem with high drug prices isn't 'foreign freeloading,' it's the patent system
27 June 2018 - One in four Americans are unable to fill prescriptions due to high prices. ...
Posted by Michael Wonder on 27 Jun 2018
Sandoz restrained from selling MabThera biosimilar in Australia
21 June 2018 - Australia's first biosimilar interlocutory injunction. ...
Posted by Michael Wonder on 17 Jun 2018
Drug patents could be Canada's special weapon in U.S. trade dispute
16 June 2018 - Taking an 'asymmetrical' approach and targeting U.S. intellectual property has worked in the past, experts say. ...
Posted by Michael Wonder on 04 Jun 2018
FDA wants to shorten new drug monopolies to cut costs
4 June 2018 - In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb ...
Posted by Michael Wonder on 26 Feb 2018
NHS could claw back £502m if Lyrica ruling upheld, study finds
26 February 2018 - The NHS could reclaim up to £502 million in excess prescribing costs relating to Pfizer’s pregabalin ...
Posted by Michael Wonder on 09 Jan 2018
How Allergan continues to make drug prices insane
9 January 2018 - The company kept a promise to limit increases to the single digits. But it didn't stop abusing ...
Posted by Michael Wonder on 25 Nov 2017
EU Ombudsman confirms EMA’s correct handling of declared interests
24 November 2017 - Latest decision concludes no maladministration at EMA. ...
Posted by Michael Wonder on 21 Nov 2017
Roche sues Pfizer to block biosimilar of cancer drug Herceptin
21 November 2017 - Company seeks to protect drug that earned $2.5 billion. ...
Posted by Michael Wonder on 08 Nov 2017
Paediatric exclusivity and regulatory authority
8 November 2017 - In May 2017, the US FDA denied a 6-month extension of market exclusivity for Sensipar (cinacalcet), ...
Posted by Michael Wonder on 28 Sep 2017
AbbVie announces global resolution of Humira (adalimumab) patent disputes with Amgen
28 September 2017 - Agreements provide non-exclusive license to Amgen for Humira related intellectual property in the U.S. effective 31 January ...